New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivoC. Korin Bullen, Robert F. Siliciano, Gregory M. Laird et al.|Nature Medicine|2014Cited by 498
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinationsGregory M. Laird, Robert F. Siliciano, C. Korin Bullen et al.|Journal of Clinical Investigation|2015Cited by 403
MDA5 RNA-sensing pathway activation by Mycobacterium tuberculosis promotes innate immune subversion and pathogen survivalC. Korin Bullen, William R. Bishai|JCI Insight|2023Cited by 26